NASDAQ:SLS SELLAS Life Sciences Group Q4 2025 Earnings Report $11.59 -0.02 (-0.17%) Closing price 04:00 PM EasternExtended Trading$11.52 -0.07 (-0.62%) As of 07:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast SELLAS Life Sciences Group EPS ResultsActual EPS-$0.05Consensus EPS -$0.06Beat/MissBeat by +$0.01One Year Ago EPSN/ASELLAS Life Sciences Group Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ASELLAS Life Sciences Group Announcement DetailsQuarterQ4 2025Date3/19/2026TimeBefore Market OpensConference Call DateWednesday, March 25, 2026Conference Call Time4:00PM ETUpcoming EarningsSELLAS Life Sciences Group's Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) SELLAS Life Sciences Group Earnings HeadlinesSELLAS Life Sciences präsentiert auf der AACR-Konferenz 2026 zu Bauchspeicheldrüsenkrebs präklinische Daten zur Wirksamkeit von SLS009 in PankreaskrebsmodellenSeptember 26 at 1:39 AM | de.marketscreener.comDSELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic CancerSeptember 25 at 1:00 PM | globenewswire.comMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now.September 28 at 1:00 AM | TradeSmith (Ad)INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSSeptember 24, 2026 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSSeptember 22, 2026 | globenewswire.comSELLAS Life Sciences: Valued For Perfection, REGAL Trial Success Probability Priced InSeptember 21, 2026 | seekingalpha.comSee More SELLAS Life Sciences Group Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like SELLAS Life Sciences Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on SELLAS Life Sciences Group and other key companies, straight to your email. Email Address About SELLAS Life Sciences GroupSELLAS Life Sciences Group (NASDAQ:SLS) is a clinical-stage biopharmaceutical company focused on developing novel therapies for cancer. The company’s research programs are aimed at treating hematologic malignancies and solid tumors through immunotherapy and targeted drug development. SELLAS’s lead immunotherapy candidate is galinpepimut-S, or GPS, an investigational peptide vaccine designed to stimulate an immune response against Wilms’ tumor 1 (WT1), a protein associated with several cancers. The company has been advancing GPS in clinical studies, including research in acute myeloid leukemia and other malignancies. The company is also developing SLS009, an investigational, highly selective cyclin-dependent kinase 9 (CDK9) inhibitor being evaluated for potential use in blood cancers and solid tumors. SELLAS conducts clinical development activities through studies involving patients in the United States and other locations, as applicable to its individual programs. SELLAS is led by Angelos M. Stergiou, M.D., Sc.D., who serves as president and chief executive officer. The company is headquartered in New York and trades on the Nasdaq Capital Market under the symbol SLS.View SELLAS Life Sciences Group ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a TailwindFertilizer Prices Keep Climbing: 3 Stocks Still Trading at a Discount Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
